Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resi… Read more
Market Cap & Net Worth: Arno Therapeutics (ARNI)
Arno Therapeutics (OTCGREY:ARNI) has a market capitalization of $4.93K ($4.93K) as of March 19, 2026. Listed on the OTCGREY stock exchange, this USA-based company holds position #47652 globally and #14707 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arno Therapeutics's stock price $0.00 by its total outstanding shares 49349749 (49.35 Million).
Arno Therapeutics Market Cap History: 2015 to 2025
Arno Therapeutics's market capitalization history from 2015 to 2025. Data shows change from $17.03 Million to $4.93K (-57.90% CAGR).
Arno Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arno Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ARNI by Market Capitalization
Companies near Arno Therapeutics in the global market cap rankings as of March 19, 2026.
Key companies related to Arno Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Arno Therapeutics Historical Marketcap From 2015 to 2025
Between 2015 and today, Arno Therapeutics's market cap moved from $17.03 Million to $ 4.93K, with a yearly change of -57.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.93K | 0.00% |
| 2024 | $4.93K | 0.00% |
| 2023 | $4.93K | -95.24% |
| 2021 | $103.63K | -12.50% |
| 2020 | $118.44K | +33.33% |
| 2019 | $88.83K | +20.00% |
| 2018 | $74.02K | +25.00% |
| 2017 | $59.22K | -99.36% |
| 2016 | $9.23 Million | -45.80% |
| 2015 | $17.03 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Arno Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.93K USD |
| MoneyControl | $4.93K USD |
| MarketWatch | $4.93K USD |
| marketcap.company | $4.93K USD |
| Reuters | $4.93K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.